Raily Aesthetic Medicine International Holdings Limited provided earning guidance for six months ended 30 June 2023. The board of directors of the Company informed the shareholders of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 and the information currently available to the Board, the Board expected the Group to record: a revenue of approximately RMB 98 million for the six months ended 30 June 2023 (six months ended 30 June 2022: revenue of approximately RMB 94 million); and a loss attributable to owners of the parent of approximately RMB 2 million for the six months ended 30 June 2023 (six months ended 30 June 2022: profit attributable to owners of the parent of approximately RMB 1.5 million).